MedTrace Logo

Eligard Observational Registry for Patients With Prostate Cancer

NCT00992251 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 354

Last updated 2016-12-22

No results posted yet for this study

Summary

The objective of this registry is to collect data on patient demographics, medical history, change in prostate, bone and overall health of the patients receiving androgen ablation treatment using Eligard. Data collected through this national registry program provides an opportunity to increase knowledge of efficacy and safety of the long term treatment with Eligard, provide a platform to better identify patient segments for the therapy with Eligard®. Furthermore registries are the only tools to accurately capture rare adverse events.

Conditions

  • Cancer of the Prostate

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • CMX Research

    lead OTHER

Principal Investigators

  • Hélène Grassin · Sanofi

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00992251 on ClinicalTrials.gov